Sysmex, LabCorp extend hematology automation pact

By LabPulse.com staff writers

September 26, 2019 -- Sysmex America and LabCorp announced they are extending their hematology automation agreement. Sysmex America is providing LabCorp Diagnostics' primary reference laboratories with Sysmex's upgraded XN series technology.

The new XN-9100 is a scalable, modular automation system incorporating Yaskawa sample-sorting robotics. The system reduces turnaround time, improving labor utilization and maintaining high-quality patient results. It features a smaller footprint that frees laboratory space for other operational needs, the companies said in a statement.

Since Sysmex America and LabCorp first entered into their hematology instrument agreement, LabCorp has increased test volumes by approximately 50% while using less laboratory space. LabCorp expects to see similar improvements in performance as it deploys the XN-9100 across its laboratory network.

XN-9100 has been successfully integrated into LabCorp's workflows in its Atlantic Division regional laboratory in Burlington, NC. The company intends to install the system in 11 additional LabCorp regional laboratories across the U.S. by early 2021.

Sysmex drives Clinical Lab 2.0 anemia project
Sysmex America is providing a grant to the Clinical Lab 2.0 value-based laboratory initiative to support a multi-institutional demonstration project related...
Sysmex releases PS-10 sample preparation system
Sysmex America has begun shipping its PS-10 sample preparation system for flow cytometry applications in the U.S. and Canada.
Sysmex RAS liquid biopsy test headed for Japan
Sysmex Inostics and Merck KGaA's OncoBeam circulating tumor DNA blood test kit for RAS genetic mutations in colorectal cancer is headed for the Japanese...
LabCorp builds on consumer tests
LabCorp is now offering consumers the ability to buy tests online, get tested by a phlebotomist at a convenient location, and receive results through...
With LabCorp's lead, Mount Sinai dives into digital pathology
LabCorp is working with the Mount Sinai healthcare system in New York City to build out digital pathology services, including the establishment of a center...
LabCorp launches Qiagen's FGFR test for bladder cancer
LabCorp announced on May 10 that it has begun offering Qiagen's therascreen companion diagnostic for detecting FGFR mutations in bladder cancer.

Copyright © 2019 LabPulse.com

Last Updated np 9/26/2019 3:17:25 PM